Autoimmune & Bone
An increasing number of diseases are now recognized as being driven by inflammatory processes, and consequently involve various cells of the immune system. These cells include macrophages, microglial cells, T-cells, B-cells, monocytes and mast cells. Plexxikon is developing novel agents that target a number of these cells to address unmet medical needs in rheumatoid arthritis (RA) as well as other inflammation disorders.
Plexxikon is developing PLX5622, a novel, oral and highly selective kinase inhibitor targeting FMS kinase, which plays a critical role in numerous diseases, including rheumatoid arthritis.
PLX5622 is currently being evaluated in a Phase 1 study to test initial safety, tolerability and pharmacokinetics.
In preclinical studies, PLX5622 has demonstrated significant disease suppression in arthritis models. The compound may also reverse joint destruction and induce repair, as well as prevent inflammation through inhibition of macrophages. In addition, PLX5622 has the potential to reduce bone erosion and pain through inhibition of osteoclasts.
Beyond RA, Plexxikon's FMS inhibitors also have demonstrated efficacy in preclinical models of systemic lupus erythematosus (SLE), inflammatory bowel disease, (IBD), and asthma.